BioCentury
ARTICLE | Clinical News

Graspa: Phase I/II started

August 11, 2014 7:00 AM UTC

Erytech began a dose-escalation U.S. Phase I/II trial to evaluate ERY-ASP in 12-18 ALL patients. In Europe, ERY-ASP is in a Phase III trial in relapsing ALL, a Phase IIb trial in acute myelogenous leu...